<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2022-4882</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-4882</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Роль кардиоспецифических биомаркеров и эпикардиального жира в диагностике хронической сердечной недостаточности у пациентов с различными формами фибрилляции предсердий</article-title><trans-title-group xml:lang="en"><trans-title>The role of cardiac biomarkers and epicardial fat in the diagnosis of heart failure in patients with various types of atrial fibrillation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4886-9648</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лосик</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Losik</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лосик Денис Владимирович — кандидат медицинских наук, врач-кардиолог, старший научный сотрудник НИО хирургической аритмологии института патологии кровообращения</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">dvlosik@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1518-0668</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фишер</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fisher</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фишер Елизавета Владимировна — врач-кардиолог.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">f.lizaveta@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3552-7158</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михеенко</surname><given-names>И. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikheenko</surname><given-names>I. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михеенко Игорь Леонидович — младший научный сотрудник.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">igor.mikheenko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5643-9109</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитин</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitin</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никитин Никита Александрович — врач-рентгенолог.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">n.nikitin91@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6626-6408</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минин</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Minin</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минин Станислав Михайлович — кандидат медицинских наук, врач-радиолог отделения радиотерапии.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">mininsm.78@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1568-9472</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белобородов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Beloborodov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белобородов Владимир Викторович — аспирант, врач-сердечно-сосудистый хирург.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">dvlosik@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6958-6690</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романов</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanov</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Романов Александр Борисович — доктор медицинских наук, заместитель генерального директора, врач-сердечно-сосудистый хирург.</p><p>Новосибирск.</p></bio><bio xml:lang="en"><p>Novosibirsk.</p></bio><email xlink:type="simple">abromanov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">НМИЦ им. акад. Е.Н. Мешалкина Минздрава России<country>Россия</country></aff><aff xml:lang="en">Meshalkin National Medical Research Center<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Медицинский центр “Авиценна”<country>Россия</country></aff><aff xml:lang="en">Avicenna Medical Center<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>03</month><year>2022</year></pub-date><volume>27</volume><issue>4</issue><fpage>4882</fpage><lpage>4882</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лосик Д.В., Фишер Е.В., Михеенко И.Л., Никитин Н.А., Минин С.М., Белобородов В.В., Романов А.Б., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Лосик Д.В., Фишер Е.В., Михеенко И.Л., Никитин Н.А., Минин С.М., Белобородов В.В., Романов А.Б.</copyright-holder><copyright-holder xml:lang="en">Losik D.V., Fisher E.V., Mikheenko I.L., Nikitin N.A., Minin S.M., Beloborodov V.V., Romanov A.B.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/4882">https://russjcardiol.elpub.ru/jour/article/view/4882</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить уровень различных кардиоспецифических биомаркеров и объем эпикардиальной жировой ткани (ЭЖТ) у пациентов c различными типами хронической сердечной недостаточности (ХСН) в зависимости от формы фибрилляции предсердий (ФП).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В проспективное наблюдательное исследование было включено 69 пациентов с симптомной ФП, а также с признаками и симптомами ХСН на уровне II-III функционального класса по классификации Нью-Йоркской ассоциации сердца (NYHA). Всем пациентам было выполнено обследование перед процедурой катетерной аблации по поводу ФП. В комплекс обследований вошли эхокардиография, компьютерная томография, двухэтапная перфузионная сцинтиграфия миокарда и иммунохимический анализ с определением кардиоспецифических биомаркеров: мозговой натрийуретический пептид (BNP), высокочувствительный тропонин I (hs-TnI), а также биохимический анализ с высокочувствительным определением С-реактивного белка (вчСРБ). Пациенты были разделены на 2 группы в зависимости от формы ФП, на пароксизмальную и непароксизмальную (персистирующая и длительно-персистирующая).</p></sec><sec><title>Результаты</title><p>Результаты. В анализ было включено 69 пациентов с различными формами ФП и симптомной ХСН. Пациентов с ХСН, подтвержденной повышенным уровнем BNP, было достоверно больше в группе с непароксизмальной формой 27 (71%) vs 5 (16%), р&lt;0,00001. Анализ сравнения показал, что в группе 2 средний уровень BNP достоверно отличался и был выше, чем в группе 1 (135,5 пг/мл [75,2;303,2] vs 40 пг/мл [20,7;56,9], соответственно, р&lt;0,00001). Уровень hs-TnI был выше в группе 2 (2,5 [1,7;5,1] vs 1,9 [0,8;3,9], соответственно, р=0,19), однако достоверной разницы между группами получено не было. Уровень вчСРБ не различался в обеих группах. В группе 1 объем ЭЖТ составил (139 [117,5;171] vs 2 группы 169 [130;209,5], р=0,03).</p></sec><sec><title>Заключение</title><p>Заключение. Форма ФП играет роль при интерпретации кардиоспецифических ферментов, и уровень BNP и объем ЭЖТ выше у пациентов с непароксизмальной формой.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess the level of various cardiac biomarkers and the volume of epicardial adipose tissue (EAT) in patients with heart failure (HF) depending on the type of atrial fibrillation (AF).</p></sec><sec><title>Material and methods</title><p>Material and methods. This prospective observational study included 69 patients with symptomatic AF, as well as with manifestations of New York Heart Association (NYHA) class II-III HF. All patients were examined before catheter ablation for AF. The following investigations were performed: echocardiography, computed tomography, myocardial perfusion scintigraphy, immunochemical analysis of cardiac biomarkers (brain natriuretic peptide (BNP), high-sensitivity troponin I (hs-TnI)), as well as biochemical analysis of high-sensitivity C reactive protein (hsCRP). Patients were divided into 2 groups, depending on the AF type, into paroxysmal and non-paroxysmal (persistent and long-standing persistent).</p></sec><sec><title>Results</title><p>Results. The analysis included 69 patients with various AF types and symptomatic HF. There were significantly more patients with HF confirmed by an elevated BNP level in the group with non-paroxysmal type (27 (71%) vs 5 (16%), p&lt;0,00001). Comparison analysis showed that in group 2 the mean BNP level was significantly higher than in group 1 (135,5 pg/ml [75,2;303,2] vs 40 pg/ml [20,7;56,9], respectively, p&lt;0,00001). The hs-TnI level was higher in group 2 (2,5 [1,7;5,1] vs 1,9 [0,8;3,9], respectively, p=0,19), but there was no significant difference between the groups. The level of hsCRP did not differ in both groups. In group 1, the EAT volume was 139 [117,5;171] vs 169 [130;209,5] in group 2 (p=0,03).</p></sec><sec><title>Conclusion</title><p>Conclusion. The type of AF plays a role in the interpretation of cardiac specific enzymes, and BNP levels and EAT volume are higher in patients with the non-paroxysmal form.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>фибрилляция предсердий</kwd><kwd>натрийуретический пептид</kwd><kwd>тропонин</kwd><kwd>эпикардиальная жировая ткань</kwd><kwd>С-реактивный белок</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>atrial fibrillation</kwd><kwd>natriuretic peptide</kwd><kwd>troponin</kwd><kwd>epicardial adipose tissue</kwd><kwd>C-reactive protein</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Грант “Российского научного фонда” № 17-75-20118.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>Grant of the Russian Science Foundation № 17-7520118.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. Journal of the American College of Cardiology. 1993;22(4):A6-A13. doi:10.1016/0735-1097(93)90455-a.</mixed-citation><mixed-citation xml:lang="en">Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. Journal of the American College of Cardiology. 1993;22(4):A6-A13. doi:10.1016/0735-1097(93)90455-a.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">Russian Society of Cardiology (RSC) (Rsc). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">van Doorn S, Geersing G-J, Kievit RF, et al. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. Heart. 2018;104(15):1236-7. doi:10.1136/heartjnl-2017-312781.</mixed-citation><mixed-citation xml:lang="en">van Doorn S, Geersing G-J, Kievit RF, et al. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. Heart. 2018;104(15):1236-7. doi:10.1136/heartjnl-2017-312781.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation. 2021;143(4):326-36. doi:10.1161/circulationaha.120.051783.</mixed-citation><mixed-citation xml:lang="en">Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation. 2021;143(4):326-36. doi:10.1161/circulationaha.120.051783.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020;42(5):373-498. doi:10.1093/eurheartj/ehaa612.</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020;42(5):373-498. doi:10.1093/eurheartj/ehaa612.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Romanov A, Minin S, Nikitin N, et al. The relationship between global cardiac and regional left atrial sympathetic innervation and epicardial fat in patients with atrial fibrillation. Annals of Nuclear Medicine. 2021;35(10):1079-88. doi:10.1007/s12149-021-01643-2.</mixed-citation><mixed-citation xml:lang="en">Romanov A, Minin S, Nikitin N, et al. The relationship between global cardiac and regional left atrial sympathetic innervation and epicardial fat in patients with atrial fibrillation. Annals of Nuclear Medicine. 2021;35(10):1079-88. doi:10.1007/s12149-021-01643-2.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Choi T-Y, Ahmadi N, Sourayanezhad S, et al. Relation of vascular stiffness with epicardial and pericardial adipose tissues, and coronary atherosclerosis. Atherosclerosis. 2013;229(1):118-123. doi:10.1016/j.atherosclerosis.2013.03.003.</mixed-citation><mixed-citation xml:lang="en">Choi T-Y, Ahmadi N, Sourayanezhad S, et al. Relation of vascular stiffness with epicardial and pericardial adipose tissues, and coronary atherosclerosis. Atherosclerosis. 2013;229(1):118-123. doi:10.1016/j.atherosclerosis.2013.03.003.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Marwan M, Koenig S, Schreiber K, et al. Quantification of epicardial adipose tissue by cardiac CT: Influence of acquisition parameters and contrast enhancement. European Journal of Radiology. 2019;121:108732. doi:10.1016/j.ejrad.2019.108732.</mixed-citation><mixed-citation xml:lang="en">Marwan M, Koenig S, Schreiber K, et al. Quantification of epicardial adipose tissue by cardiac CT: Influence of acquisition parameters and contrast enhancement. European Journal of Radiology. 2019;121:108732. doi:10.1016/j.ejrad.2019.108732.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kawasaki M, Yamada T, Furukawa Y, et al. Are cardiac sympathetic nerve activity and epicardial adipose tissue associated with atrial fibrillation recurrence after catheter ablation in patients without heart failure? International Journal of Cardiology. 2020;303:41-8. doi:10.1016/j.ijcard.2019.11.092.</mixed-citation><mixed-citation xml:lang="en">Kawasaki M, Yamada T, Furukawa Y, et al. Are cardiac sympathetic nerve activity and epicardial adipose tissue associated with atrial fibrillation recurrence after catheter ablation in patients without heart failure? International Journal of Cardiology. 2020;303:41-8. doi:10.1016/j.ijcard.2019.11.092.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(12):1929-40. doi:10.1007/s00259-015-3139-x.</mixed-citation><mixed-citation xml:lang="en">Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(12):1929-40. doi:10.1007/s00259-015-3139-x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.</mixed-citation><mixed-citation xml:lang="en">Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. Circulation. 2002;105(4):539-42. doi:10.1161/hc0402.102975.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641.</mixed-citation><mixed-citation xml:lang="en">Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Merino-Merino A, Saez-Maleta R, Salgado-Aranda R, et al. Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: Diagnostic application and new cut-off points. Heart &amp; Lung. 2020;49(4):388-92. doi:10.1016/j.hrtlng.2020.02.043.</mixed-citation><mixed-citation xml:lang="en">Merino-Merino A, Saez-Maleta R, Salgado-Aranda R, et al. Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: Diagnostic application and new cut-off points. Heart &amp; Lung. 2020;49(4):388-92. doi:10.1016/j.hrtlng.2020.02.043.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Plitt DC, Chung EH, Mounsey JP, et al. Relation of Atrial Fibrillation Burden and N-Terminal Pro-Brain Natriuretic Peptide. The American Journal of Cardiology. 2013;111(9):1315-8. doi:10.1016/j.amjcard.2013.01.273.</mixed-citation><mixed-citation xml:lang="en">Plitt DC, Chung EH, Mounsey JP, et al. Relation of Atrial Fibrillation Burden and N-Terminal Pro-Brain Natriuretic Peptide. The American Journal of Cardiology. 2013;111(9):1315-8. doi:10.1016/j.amjcard.2013.01.273.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Лосик Д. В., Никитин Н. А., Минин С. М. и др. Роль эпикардиальной жировой ткани и автономной нервной системы в патогенезе нарушений ритма сердца. Патология кровообращения и кардиохирургия. 2021;25(3):27-33. doi:10.21688/1681-3472-2021-3-27-33.</mixed-citation><mixed-citation xml:lang="en">Losik DV, Nikitin NA, Minin SM, et al. The role of epicardial adipose tissue and autonomic nervous system in pathophysiology of cardiac arrhythmias. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2021;25(3):27-33. (In Russ.) doi:10.21688/1681-3472-2021-3-27-33.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Лосик Д. В., Никитин Н. А., Минин С. М. и др. Взаимосвязь эпикардиальной жировой ткани и прогноза сердечно-сосудистых событий. Кардиология и сердечно-сосудистая хирургия. 2021;14(4):2538. doi:10.17116/kardio202114041253.</mixed-citation><mixed-citation xml:lang="en">Losik DV, Nikitin NA, Minin SM, et al. Relationship between epicardial adipose tissue and prognosis of cardiovascular events. Kardiologiya i serdechno-sosudistaya khirurgiya. 2021;14(4):253-8. (In Russ.) doi:10.17116/kardio202114041253.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Beyer C, Tokarska L, Stühlinger M, et al. Structural Cardiac Remodeling in Atrial Fibrillation. JACC: Cardiovascular Imaging. 2021;14(11):2199-208. doi:10.1016/j.jcmg.2021.04.027.</mixed-citation><mixed-citation xml:lang="en">Beyer C, Tokarska L, Stühlinger M, et al. Structural Cardiac Remodeling in Atrial Fibrillation. JACC: Cardiovascular Imaging. 2021;14(11):2199-208. doi:10.1016/j.jcmg.2021.04.027.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Никитин Н. А., Лосик Д. В., Михеенко И. Л., Романов А. Б. Взаимосвязь между симпатической иннервацией сердца и эпикардиальной жировой клетчаткой у пациентов с фибрилляцией предсердий. Кардиоторакальная радиология. 2021:69. EDN: XCYBJO.</mixed-citation><mixed-citation xml:lang="en">Nikitin NA, Losik DV, Mikheenko IL, Romanov AB. Relationship between sympathetic innervation of the heart and epicardial adipose tissue in patients with atrial fibrillation. Cardiothoracic radiology. 2021:69. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tan ESJ, Chan S-P, Liew O-W, et al. Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clinical Chemistry. 2020;67(1):216-26. doi:10.1093/clinchem/hvaa287.</mixed-citation><mixed-citation xml:lang="en">Tan ESJ, Chan S-P, Liew O-W, et al. Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clinical Chemistry. 2020;67(1):216-26. doi:10.1093/clinchem/hvaa287.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Packer M. Characterization, Pathogenesis, and Clinical Implications of Inflammation‐ Related Atrial Myopathy as an Important Cause of Atrial Fibrillation. J Am Heart Assoc. 2020;9(7):e015343. doi:10.1161/jaha.119.015343.</mixed-citation><mixed-citation xml:lang="en">Packer M. Characterization, Pathogenesis, and Clinical Implications of Inflammation‐ Related Atrial Myopathy as an Important Cause of Atrial Fibrillation. J Am Heart Assoc. 2020;9(7):e015343. doi:10.1161/jaha.119.015343.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Lip GYH, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options — a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2011;14(1):8-27. doi:10.1093/europace/eur241.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Lip GYH, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options — a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2011;14(1):8-27. doi:10.1093/europace/eur241.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
